Type 2 diabetes: new drugs, new perspectives
Detection at younger ages is rapidly increasing. Although diet and exercise remain the mainstays of therapy, physicians can now choose from among a variety of medications targeting different pathophysiologic facets of the disease. The newest drugs are the thiazolidinediones, a totally novel class of...
Gespeichert in:
| Veröffentlicht in: | Hospital practice (1995) 2001-09, Vol.36 (9), p.29-36 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 36 |
|---|---|
| container_issue | 9 |
| container_start_page | 29 |
| container_title | Hospital practice (1995) |
| container_volume | 36 |
| creator | Goldfine, A B |
| description | Detection at younger ages is rapidly increasing. Although diet and exercise remain the mainstays of therapy, physicians can now choose from among a variety of medications targeting different pathophysiologic facets of the disease. The newest drugs are the thiazolidinediones, a totally novel class of insulin sensitizers. |
| doi_str_mv | 10.1080/21548331.2001.11444143 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71183584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71183584</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-4b53509b6cadef4d8a9df8f8d3ac83219037e2f904e2aac7130d7a7c25617493</originalsourceid><addsrcrecordid>eNpFkE1LAzEQhoMoVmr_QtmTp27NZJJN1psUv6DgpfeQTWZlpR9rsqv037u1LZ7mZXjeGXgYmwKfAzf8XoCSBhHmgnOYA0gpQeIFuxGodQ6c4-WQByg_UCM2SemTD1vkClFfsxGAKpSW_IbNVvuWMpGFxlXUUXrItvSThdh_pNlfbCmmlnzXfFO6ZVe1WyeanOaYrZ6fVovXfPn-8rZ4XOYeS9HlslKoeFkV3gWqZTCuDLWpTUDnDQooOWoSdcklCee8BuRBO-2FKkDLEsfs7ni2jbuvnlJnN03ytF67Le36ZDWAQWXkABZH0MddSpFq28Zm4-LeArcHU_Zsyh5M2bOpoTg9feirDYX_2skL_gK9CWFd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71183584</pqid></control><display><type>article</type><title>Type 2 diabetes: new drugs, new perspectives</title><source>MEDLINE</source><source>Taylor & Francis:Master (3349 titles)</source><creator>Goldfine, A B</creator><creatorcontrib>Goldfine, A B</creatorcontrib><description>Detection at younger ages is rapidly increasing. Although diet and exercise remain the mainstays of therapy, physicians can now choose from among a variety of medications targeting different pathophysiologic facets of the disease. The newest drugs are the thiazolidinediones, a totally novel class of insulin sensitizers.</description><identifier>ISSN: 2154-8331</identifier><identifier>EISSN: 2377-1003</identifier><identifier>DOI: 10.1080/21548331.2001.11444143</identifier><identifier>PMID: 11565740</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Animals ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - etiology ; Diabetes Mellitus, Type 2 - metabolism ; Diabetes Mellitus, Type 2 - physiopathology ; Diet, Diabetic ; Exercise ; Glucose - metabolism ; Humans ; Hypoglycemic Agents - therapeutic use ; Insulin Resistance</subject><ispartof>Hospital practice (1995), 2001-09, Vol.36 (9), p.29-36</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-4b53509b6cadef4d8a9df8f8d3ac83219037e2f904e2aac7130d7a7c25617493</citedby><cites>FETCH-LOGICAL-c392t-4b53509b6cadef4d8a9df8f8d3ac83219037e2f904e2aac7130d7a7c25617493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11565740$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goldfine, A B</creatorcontrib><title>Type 2 diabetes: new drugs, new perspectives</title><title>Hospital practice (1995)</title><addtitle>Hosp Pract (1995)</addtitle><description>Detection at younger ages is rapidly increasing. Although diet and exercise remain the mainstays of therapy, physicians can now choose from among a variety of medications targeting different pathophysiologic facets of the disease. The newest drugs are the thiazolidinediones, a totally novel class of insulin sensitizers.</description><subject>Adult</subject><subject>Animals</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - etiology</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Diet, Diabetic</subject><subject>Exercise</subject><subject>Glucose - metabolism</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin Resistance</subject><issn>2154-8331</issn><issn>2377-1003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LAzEQhoMoVmr_QtmTp27NZJJN1psUv6DgpfeQTWZlpR9rsqv037u1LZ7mZXjeGXgYmwKfAzf8XoCSBhHmgnOYA0gpQeIFuxGodQ6c4-WQByg_UCM2SemTD1vkClFfsxGAKpSW_IbNVvuWMpGFxlXUUXrItvSThdh_pNlfbCmmlnzXfFO6ZVe1WyeanOaYrZ6fVovXfPn-8rZ4XOYeS9HlslKoeFkV3gWqZTCuDLWpTUDnDQooOWoSdcklCee8BuRBO-2FKkDLEsfs7ni2jbuvnlJnN03ytF67Le36ZDWAQWXkABZH0MddSpFq28Zm4-LeArcHU_Zsyh5M2bOpoTg9feirDYX_2skL_gK9CWFd</recordid><startdate>20010915</startdate><enddate>20010915</enddate><creator>Goldfine, A B</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010915</creationdate><title>Type 2 diabetes: new drugs, new perspectives</title><author>Goldfine, A B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-4b53509b6cadef4d8a9df8f8d3ac83219037e2f904e2aac7130d7a7c25617493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Animals</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - etiology</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Diet, Diabetic</topic><topic>Exercise</topic><topic>Glucose - metabolism</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin Resistance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldfine, A B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hospital practice (1995)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldfine, A B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Type 2 diabetes: new drugs, new perspectives</atitle><jtitle>Hospital practice (1995)</jtitle><addtitle>Hosp Pract (1995)</addtitle><date>2001-09-15</date><risdate>2001</risdate><volume>36</volume><issue>9</issue><spage>29</spage><epage>36</epage><pages>29-36</pages><issn>2154-8331</issn><eissn>2377-1003</eissn><abstract>Detection at younger ages is rapidly increasing. Although diet and exercise remain the mainstays of therapy, physicians can now choose from among a variety of medications targeting different pathophysiologic facets of the disease. The newest drugs are the thiazolidinediones, a totally novel class of insulin sensitizers.</abstract><cop>England</cop><pmid>11565740</pmid><doi>10.1080/21548331.2001.11444143</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2154-8331 |
| ispartof | Hospital practice (1995), 2001-09, Vol.36 (9), p.29-36 |
| issn | 2154-8331 2377-1003 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71183584 |
| source | MEDLINE; Taylor & Francis:Master (3349 titles) |
| subjects | Adult Animals Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - etiology Diabetes Mellitus, Type 2 - metabolism Diabetes Mellitus, Type 2 - physiopathology Diet, Diabetic Exercise Glucose - metabolism Humans Hypoglycemic Agents - therapeutic use Insulin Resistance |
| title | Type 2 diabetes: new drugs, new perspectives |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A42%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Type%202%20diabetes:%20new%20drugs,%20new%20perspectives&rft.jtitle=Hospital%20practice%20(1995)&rft.au=Goldfine,%20A%20B&rft.date=2001-09-15&rft.volume=36&rft.issue=9&rft.spage=29&rft.epage=36&rft.pages=29-36&rft.issn=2154-8331&rft.eissn=2377-1003&rft_id=info:doi/10.1080/21548331.2001.11444143&rft_dat=%3Cproquest_cross%3E71183584%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71183584&rft_id=info:pmid/11565740&rfr_iscdi=true |